Meeting
2011 ASCO Annual Meeting
A phase II trial of sorafenib (S) and dacarbazine (D) in leiomyosarcoma (LMS), synovial sarcoma (SS), and malignant peripheral nerve sheath tumor (MPNST).
Authors
D. R. D'Adamo
Memorial Sloan-Kettering Cancer Center, New York, NY
D. R. D'Adamo , M. L. Keohan , R. D. Carvajal , M. L. Hensley , C. Hirst , L. Qin , C. Antonescu , R. A. Lefkowitz , G. K. Schwartz , R. G. Maki
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT00837148
Citation
J Clin Oncol 29: 2011 (suppl; abstr 10025)
Abstract #
10025
Poster Bd #
17
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
CaboRISE: A phase II study evaluating reduced starting dose and dose escalation of cabozantinib as second-line therapy for advanced HCC in patients with compensated liver cirrhosis.
First Author: Jorg Trojan
Poster
2014 ASCO Annual Meeting
Alliance A091102: Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.
First Author: Mark Andrew Dickson
Poster
2012 ASCO Annual Meeting
Randomized phase II study of the x-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).
First Author: Ann Sing Lee
Poster
2023 ASCO Annual Meeting
Interim results of a phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin for advanced leiomyosarcoma.
First Author: Neal Shiv Chawla